Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials

Acta Oncologica

Volumn 51, Issue 7, 2012, Pages 873-879

  Iacovelli, Roberto ^a   Palazzo, Antonella ^a   Mezi, Silvia ^a   Morano, Federica ^a   Naso, Giuseppe ^a   Cortesi, Enrico ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; TEMSIROLIMUS;

ARTICLE; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; HUMAN; LUNG DISEASE; LUNG METASTASIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; LUNG; NEOPLASMS; NEUROENDOCRINE TUMORS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; RISK; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84866348815     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.705019     Document Type: Article

References (32)

1. Coleman LJ, Peter M B, Teall TJ, Brannan R A, Hanby AM, Honarpisheh H, et al. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer 2009; 100: 1393-9.
2. Khoury T, Alrawi S, Ramnath N, Li Q, Grimm M, Black J, et al. Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. Clin Lung Cancer 2009; 10: 58-66.
3. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, et al. Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006; 107: 1801-11. (Pubitemid 44582949)
4. Sabatini DM. m TOR and cancer: Insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-34. (Pubitemid 44286004)
5. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009; 15: 1612-22.
6. Palazzo A, Iacovelli R, Cortesi E. P ast, present and future of targeted therapy in solid tumors. Curr Cancer Drug Targets 2010; 10: 433-61.
7. Yao J C, Shah M H, Ito T, Bohas C L, Wolin E M, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-23.
8. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hö r sch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet 2011; 378: 2005-12.
9. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27: 2630-7.
10. Baselga J, Campone M, Piccart M, Burris H A, Rugo H S, Sahmoud T, et al. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. N Engl J Med Epub 2011 Dec 7.
11. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-9.
12. Expó s ito V, de Prada JA, Góm ez-Romá n JJ, González-Vilchez F, Llano-Cardenal M, Garc í a-Camarero T, et al. Everolimusrelated pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant 2008; 27: 797-800.
13. Maroto JP, Hudes G, Dutcher JP, Logan TF, White CS, Krygowski M, et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011; 29: 1750-6.
14. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009; 339: b2535.
15. Morris J A, Gardner M J. C alculating confi dence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed) 1988; 296: 1313-6.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. M easuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60. (Pubitemid 37088507)
17. DerSimonian R, Laird N. M eta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88. (Pubitemid 17189972)
18. B egg CB, Mazumdar M. O perating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
19. Egger M, Davey Smith G, Schneider M, Minder C. B ias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34. (Pubitemid 27387172)
20. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KGM. D evelopment and validation of MIX: Comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 2006; 6: 50.
21. Bax L. M IX 2.0. Professional software for meta-analysis in Excel. Version (2.0.1.4). BiostatXL, 2011. Available from: http://www.meta-analysis- made-easy.com (cited in January 2012)
22. Motzer R J, Escudier B, Oudard S, Hutson T E, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010; 116: 4256-65.
23. Morelon E, Stern M, Kreis H. I nterstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000; 343: 225-6. (Pubitemid 30489228)
24. White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182: 396-403.
25. Atkins MB, Hidalgo M, Stadler WM, Logan T F, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, anovel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-18. (Pubitemid 41103603)
26. Vahid B, Marik PE. P ulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008; 133: 528-38. (Pubitemid 351272414)
27. Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006; 42: 1875-80. (Pubitemid 44149096)
28. Ellard S L, Clemons M, Gelmon K A, Norris B, Kennecke H, Chia S, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27: 4536-41.
29. Morelon E, Stern M, Isra ë l-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF, et al. Characteristics of sirolimusassociated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72: 787-90.
30. Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77: 1215-20. (Pubitemid 38580300)
31. Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011; 47: 1287-98. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html (cited in January 2012)
32. Sarkaria JN, Galanis E, Wu W, Dietz A B, Kaufmann T J, Gustafson MP, et al. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res 2010; 16: 5573-80.